Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Shares of Amgen (NASDAQ:AMGN) moved higher by 1.8% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 3.06% over the past year to $4.38, which beat the estimate of $4.06.

Recap: Amgen Q2 Earnings

Disney

Home Depot

Walmart

The Dow Jones is knocking on record levels again, and positive earnings from some of its most popular components could be the catalyst to get it there.

Dow Jones Jumps Back Above 35,000 -- This Could Push It Back to Record Levels Soon

U.S. biotech Amgen Inc on Tuesday said its second-quarter revenue rose 5%, but recovery from the COVID-19 pandemic, which has limited patient interactions with healthcare providers, is expected to remain gradual for the rest of 2021.

Amgen says it expects pandemic to limit sales through 2021

THOUSAND OAKS, Calif., Aug. 3, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2021.

Amgen Reports Second Quarter 2021 Financial Results

Activision Blizzard

ConocoPhillips

Match Group

Prudential Financial

Under Armour

Better-Than-Expected Earnings Push Pre-Markets Higher

Skyworks Solutions

American Eagle Outfitters

Axalta Coating Systems

Burlington Stores

Coca-Cola Bottling

Motorola Solutions

Sanderson Farms

Stryker

AT&T

Western Alliance Bancorporation

Make the most of the market. Q.ai's deep learning algorithms have identified Top Tech Stocks, Top Consumer Stocks, Top Quality Value Stocks, Top Growth Stocks, and Top Dividend Stocks for the month.

Skyworks Solutions Inc Among This Month's Top Stocks

Trading volumes indicate that traders have been selling calls and buying puts in anticipation of an unfavorable earnings report.

Amgen (AMGN) Option Traders Unenthusiastic Headed into Earnings

Amgen Inc. (NASDAQ:AMGN) shares traded flat on Friday despite declaring a $1.76 Q3 dividend per share. The company will pay the dividend on 8th September to shareholders of record on 17th August.

Amgen stock price forecast for Q3 2021 after declaring dividend ahead of Q2 results

THOUSAND OAKS, Calif., July 30, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that its Board of Directors declared a $1.76 per share dividend for the third quarter of 2021.

Amgen Announces 2021 Third Quarter Dividend

Volume growth from Amgen's (AMGN) key drugs like Prolia, Otezla Repatha and other and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.

What's in Store for Amgen (AMGN) This Earnings Season?

THOUSAND OAKS, Calif., July 29, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of S.

Amgen Appoints S. Omar Ishrak To Board Of Directors

Merck

A handful of healthcare giants are some of the few Dow stocks in the red so far today, as federal data underpins the prospects of a continued economic recovery.

Healthcare Stock Sell-Off Keeps the Dow Jones From Reaching Record Levels

THOUSAND OAKS, Calif., July 29, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Tuesday, August 3, 2021, after the close of the U.S. financial markets.

Amgen Announces Webcast Of 2021 Second Quarter Financial Results

Shares of Amgen Inc. were down 0.1% in premarket trading on Wednesday, the day after the company announced that it will pay up to $1.6 billion to buy TeneoBio, a privately held biotechnology company. Amgen is paying $900 million upfront, though potential milestone payments could push the deal's value up to $1.6 billion.

Amgen to pay up to $1.6 billion to acquire the privately held Teneobio

Amgen Inc (NASDAQ: AMGN) has agreed to acquire privately-held Teneobio, a biotechnology company developing a new class of biologics called Human Heavy-Chain Antibodies. Amgen will pay $900 million cash while committing up to $1.6 billion in milestones.

Amgen Buys Antibody Player Focused On PSMA In $2.5B Deal

Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments

Cardinal Health

McKesson

Newell Brands

Starbucks

These companies could borrow money at lower rates and use the proceeds to buy back stock—making their shares more attractive to investors.

5 Stocks to Play Low Interest Rates—While They Last

AbbVie

Bristol-Myers

Fidelity MSCI Health Care ETF

Gilead Sciences

iShares U.S. Healthcare ETF

Johnson & Johnson

Pfizer

Thermo Fisher Scientific

UnitedHealth Group

Vanguard Health Care ETF

Health Care Select Sector SPDR Fund

The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come.

Healthcare ETFs in Focus as Q2 Earnings Unfold

Caterpillar

Cisco Systems

Chevron

Direxion Daily S&P Oil & Gas Exp. & Prod. Bear 2X Shares

Direxion Daily Energy Bear 2X Shares

BMO REX MicroSectors FANG+ Index -3X Inverse Leveraged ETN

FuboTV

Honeywell

McDonald's

Microsoft

MicroSectors U.S. Big Oil Index -3X Inverse Leveraged ETNs

Direxion Daily 20+ Year Treasury Bull 3X Shares

Direxion Daily Small Cap Bear 3x Shares

Direxion Daily Utilities Bull 3X Shares

Visa

Utilities Select Sector SPDR Fund

Two new sample breakout stocks for Week 29 with better than 10% short-term upside potential. New ETF/ETN forecast section has been added. This past week the peak gains were in ATOS +26.6% and FUV +5.8% with Market and S&P 500 Momentum Gauges in extremely high negative warning conditions.

Week 29 MDA Breakout Stocks - July 2021: Short-Term Stocks And Funds To Give You An Edge

The FDA has issued an untitled letter to Amgen Inc (NASDAQ:AMGN) for the misbranding of its blockbuster bone marrow stimulant, Neulasta (pegfilgrastim) injection. Amgen released a promotional communication that makes false or misleading claims and representations about the benefit of Neulasta when administered through the Onpro on-body injector compared to a prefilled syringe (PFS).

FDA Rebukes Amgen Over Misleading Branding Of Neulasta

Amgen shares are currently trading at an attractive 5-6% discount to recent highs - underwhelming Q1 '21 earnings are responsible for this. Despite management guidance for a relatively low ~3% organic growth figure in FY21, Amgen remains a highly profitable company with sector leading profit margins.

Amgen: A Solid Buy And Hold With Significant Shareholder Benefits

THOUSAND OAKS, Calif., July 14, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN), in partnership with the International Federation of Psoriasis Associations (IFPA), announced the launch of the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Innovation Challenge, a new global initiative that aims to make a big impact within the psoriatic disease community by fostering the development of actionable solutions to address a challenge that people living with psoriatic disease and healthcare providers continue to face.

Amgen And The International Federation of Psoriasis Associations Launch UPLIFT Innovation Challenge

Amgen is slightly undervalued today; it's a great value stock to keep on your radar. The company generates consistent free cash flows.

Amgen: Undervalued Stock For Your Radar

BeiGene

The China National Medical Products Administration (NMPA) has conditionally approved Kyprolis (carfilzomib) for relapsed or refractory (R/R) multiple myeloma. The approval covers Kyprolis in combination with dexamethasone for adult patients who have received at least two prior therapies, including a proteasome inhibitor and an immunomodulatory agent.

BeiGene-Amgen's Kyprolis Gets Approval In China For Pre-Treated Multiple Myeloma Patients

The FDA accepts and grants priority review to Amgen (AMGN)/AstraZeneca's BLA for tezepelumab for the treatment of asthma.

Amgen (AMGN)/AstraZeneca's Asthma Drug Gets FDA Priority Tag

News for Amgen Stock (AMGN)